WallachBeth Capital Facilitates ABVC BioPharma's Successful $3.39 Million Capital Raise

WallachBeth Capital Facilitates ABVC BioPharma's Successful Capital Raise

On November 2, 2026, WallachBeth Capital LLC announced the successful closing of a private placement for ABVC BioPharma, Inc., generating approximately $3.39 million in gross proceeds. This transaction involved original issue discount senior convertible promissory notes (OID Notes) and marks a significant fundraising achievement for the company, aimed at boosting its operational capabilities.

The OID Notes, which have an aggregate principal amount of $4,106,060, are set to mature on June 30, 2027. They are convertible into shares of ABVC’s common stock after a transition period of eight months from the issuance. The conversion price will be determined at 85% of the average volume-weighted average prices (VWAPs) over three trading days preceding the conversion date, subject to the company’s specified Floor Price and certain adjustments. These funds are expected to expedite ABVC's growth trajectory by augmenting working capital and facilitating subsidiary operations.

Among other strategic uses for the net proceeds, ABVC plans to allocate $625,000 towards a settlement payment to Lind Global Fund II LP, as part of a release and settlement agreement. This payment aims to settle existing claims, ensuring the company can focus on its broader financing strategies and business development initiatives without future hindrance.

ABVC’s overarching strategy involves advancing its pharmaceutical and medical device portfolio, which requires constant innovation and investment. The company targets various therapeutic areas through its dedicated business platforms, including AiBtl BioPharma Inc. focused on central nervous system drug programs, OncoX BioPharma for oncology solutions, ForSeeCon Eye addressing ophthalmic needs, and BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing services combined with AI biotechnology innovations.

Through these diversified operations, ABVC is not just looking to increase its developmental capabilities but also aiming to create revenue streams through licensing opportunities, milestone payments, future royalties, and equity value enhancement. The company remains committed to exploring strategic financing avenues and capital market opportunities, essential for supporting long-term development plans and commercialization objectives.

WallachBeth Capital, a prominent player in capital markets and investment banking services within the healthcare sector, acted as the placement agent in this offering, fostering relationships between corporate clients and leading institutions. They play a pivotal role in supporting issuers and investors to meet their financial aspirations, reflecting their experience in various financial transactions including public offerings and private placements.

As of now, the OID Notes and the associated common stock have not been registered under the Securities Act of 1933 nor any state laws, which means they cannot be offered or sold in the U.S. without proper registration or exemption. Future reports detailing these transactions will be made available, including a Current Report on Form 8-K that will be filed with the U.S. Securities and Exchange Commission (SEC).

Forward-looking statements regarding the future endeavors of ABVC are part of this promotional release, underscoring the inherent uncertainties in such forecasts—a reminder that actual outcomes may differ significantly based on various influencing factors.

For those interested in tracking the progress of ABVC BioPharma following this capital raise, additional information can be accessed via the SEC’s official website and future corporate filings.